


CLAIMS

1. A compound of formula (I)



or a salt thereof

5 wherein:

R¹ is -C₁-₃alkyl or cyclopropyl;

R² is H or -C₀-₃alkyl-C₃-₇cycloalkyl, wherein the cycloalkyl group is unsubstituted or substituted with one, two or three R⁵ groups which may be the same or different;

R³ is -H, -C₁-₄alkyl, cyclopropyl or -(CH₂)ₚOR¹⁰;

10 R⁴ is a) phenyl (which may be unsubstituted or substituted by one, two or three R⁷ groups which may be the same or different); b) a 5 or 6 membered heteroaryl group (which may be unsubstituted or substituted by -C₁-₃alkyl, -O-C₁-₃alkyl or halo); c) a 9 to 11 membered heteroaryl group (which may be unsubstituted or substituted by one, two or three groups, which may be the same or different, selected from -C₁-₃alkyl-R⁸, -OCH₃, -O-C₂-₃alkyl-R⁸, halo, oxo, -O-CF₃ and -CN);

15 or d) -(CH₂)ₙ-phenyl;

p is 1 or 2;

n is 1 or 2;

R⁵ is halo, phenyl, -C₁-₆alkyl-R⁸, -CO₂H, -OCH₃, -O-C₂-₆alkyl-R⁸, -CN, -OH or -NHR⁶;

20 R⁶ is -H, -C(O)OC(CH₃)₃, -C₁-₆alkyl, -C₃-₇cycloalkyl, a 4 to 7 membered heterocyclyl group, or -C₂-₃alkyl-O-C₁-₃alkyl wherein the -C₁-₆alkyl and -C₃-₇cycloalkyl groups may be optionally substituted by one, two or three fluoro;

R⁷ is -NR¹¹R¹², -C₁-₃alkyl, halo, -CO₂R¹⁰, -CH₂OH, -CH(R¹¹)OR¹⁰, -C(O)C₁-₃alkyl, -CH(R¹⁰)NR¹¹R¹², -CN, -CHF₂, -CF₃, -OH, -OCHF₂, -OCF₃, -OCH₃, -O-C₂-₆alkyl-R⁹, -C₁-₆alkyl-R⁹ or -O-piperidinyl;

R⁸ is -H, -OR¹⁰, -CO₂C(CH₃)₃ or -NR¹¹R¹²;

25 R⁹ is -H, -OR¹⁰ or -NR¹¹R¹²;

R¹⁰ is -H or -C₁-₃alkyl;

R¹¹ and R¹² are each independently selected from -H, -C₁-₃alkyl and -C₁-₃alkylNR¹³R¹⁴; or R¹¹ and R¹² may join together with the nitrogen to which they are attached, to form a 4 to 7 membered heterocyclyl group optionally substituted by one or two substituents independently selected from

30 -C₁-₃alkyl, -OH and F; and

R¹³ and R¹⁴ are each independently selected from -H, -C₁₋₃alkyl and -C(O)CH₃.

2. A compound or salt thereof according to claim 1 wherein R¹ is methyl, ethyl or cyclopropyl.

3. A compound or salt thereof according to claim 1 or claim 2 wherein R² is cyclopropyl, cyclobutyl, cyclohexyl, methylcyclobutyl, methycyclopentyl, methylcyclohexyl, ethylcyclopropyl, ethyl cyclohexyl or spiro[3.3]heptanyl, wherein the cyclopropyl cyclobutyl, cyclopentyl, and cyclohexyl groups may be unsubstituted or substituted with 1 or 2 R⁵ groups which may be the same or different.

4. A compound or salt thereof according to any preceding claim wherein R³ is -H, methyl, ethyl or cyclopropyl.

5. A compound or salt thereof according to any preceding claim wherein R⁴ is a) phenyl (which may be unsubstituted or substituted by 1 or 2 R⁷ groups which may be the same or different); or b) a 5 or 6 membered heteroaryl (which may be unsubstituted or substituted by methyl or methoxy) or c) a 9 to 11 membered heteroaryl (which may be unsubstituted or substituted by methyl).


6. A compound or salt thereof according to any preceding claim wherein R⁴ is phenyl, unsubstituted or substituted with 1 or 2 R⁷ groups which may be the same or different.

7. A compound or salt thereof according to any preceding claim wherein R⁵ is halo, phenyl, -C₁₋₆alkyl, -O-C₁₋₆alkyl, -CO₂H, -C₁₋₆alkyl-OH, -CN, -OH or -NHR⁶.

8. A compound or salt thereof according to any preceding claim wherein R⁷ is -NHCH₃, -N(CH₃)₂, -CH₃, -OCH₃, -F, -CH₂OH, -CN, -CH₂-morpholinyl, -Cl, -C(O)CH₃, -OCH₂CH₂N(CH₃)₂, -OCH₂CH₂OH, -C(O)OCH₃, -CH₂N(CH₃)₂, -OH -CHF₂, -CF₃ or -CH(CH₃)OH.

9. A compound which is selected from Examples 1 to 341, or a salt thereof.

10. A compound which is



or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 10 and one or more pharmaceutically acceptable excipients.

12. A compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 10, for use in therapy.

13. A compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 10, for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated.

14. A compound for use according to claim 13, wherein the disease or condition is cancer or an acute or chronic autoimmune and/or inflammatory condition.

15. A compound for use according to claim 14, wherein the disease or condition is rheumatoid arthritis.

16. The use of a compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 10, in the manufacture of a medicament for the treatment of a disease or condition for which a bromodomain inhibitor is indicated.